NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Adagene Inc. (ADAG) Stock Analysis

Adagene Inc. (ADAG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ADAG

$3.58

−$0.11 (−2.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADAG with… →

ADAG Key Statistics

As of Sep 4, 2026
Trading
Open
$3.67
Previous Close
$3.69
Day's Range
3.56–3.69
52-Week Range
1.30–4.85
Volume
28.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$240.37M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
25.87
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.36
Financials (FY)
Revenue (FY)
$7.67M+7332.76%
Net Income (FY)
−$17.61M
Profit marginThe share of revenue left as profit after all costs and taxes.
−220.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
67.14M
1-Year Return
+67.29%
Dividend and dates
Avg Volume
266.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADAG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+89.42%
2025−5.03%
2024+3.06%
2023+45.74%
2022−83.58%
2021 (partial year)−73.10%

As of September 4, 2026.

ADAG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.67M−$17.61M−229.6%
2024$103.20K−$33.42M−32386.4%
2023$18.11M−$18.95M−104.6%
2022$9.29M−$79.97M−860.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.67M—−$21.44M−$17.61M−229.6%
2024$103.20K—−$35.95M−$33.42M−32386.4%
2023$18.11M—−$23.72M−$18.95M−104.6%
2022$9.29M—−$83.92M−$79.97M−860.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADAG Valuation vs Biotechnology Median

Median of 656 stocks
MetricADAGBiotechnology medianvs median
P/S ratio25.8715.2670% above
Profit margin−220.77%0.00%220.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Adagene Inc. (ADAG) carries a market capitalisation of $240.37M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 128 employees.

ADAG last closed at $3.58 on September 4, 2026. That is −$0.11 (−2.98%) against the previous close. Over the past 52 weeks the price has ranged from $1.30 to $4.85. The latest close sits 175.38% above that 52-week low.

Financial Health

In fiscal 2025, Adagene Inc. reported revenue of $7.67M. Against the prior fiscal year total of $103.20K, that is a change of +7,332.76%. The same year closed with a net loss of $17.61M. Profit margin runs at −220.77%. That is 220.8 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.36.

Across the 4 fiscal years on file, revenue moves from $9.29M in 2022 to $7.67M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 25.87. On price-to-sales that is 69.5% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +67.29%. Across 5 years the annualized return works out at −26.57%. Beta against the wider market is reported at 0.56. Annualized volatility over the trailing 5 years is 89.04%.

Growth & Income

The record shows no dividend for ADAG.

Across the complete calendar years on file, 2023 returned +45.74% and 2022 returned −83.58%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +89.42% year to date.

Peer Comparison

Adagene Inc. (ADAG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Adagene Inc. ADAG $240.37M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Adagene Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Adagene Inc.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Visit website →